Check for updates

OPEN ACCESS

EDITED BY José María Huerta, Carlos III Health Institute (ISCIII), Spain

REVIEWED BY Mahdi Vajdi, Isfahan University of Medical Sciences, Iran Manfred Eggersdorfer, University Medical Center Groningen, Netherlands

*CORRESPONDENCE Zhao Hu ⊠ huzh23@mail.sysu.edu.cn Yiqiang Zhan ⊠ yiqiang.zhan@ki.se; ⊠ zhanyq8@mail.sysu.edu.cn

RECEIVED 27 March 2024 ACCEPTED 27 June 2024 PUBLISHED 10 July 2024

CITATION

Zhao Q, Lv X, Liu Q, Hu Z and Zhan Y (2024) Association between serum folate concentrations and all-cause mortality in U.S. adults: a cohort study based on National Health and Nutrition Examination Survey III. *Front. Nutr.* 11:1408023. doi: 10.3389/fnut.2024.1408023

COPYRIGHT

© 2024 Zhao, Lv, Liu, Hu and Zhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Association between serum folate concentrations and all-cause mortality in U.S. adults: a cohort study based on National Health and Nutrition Examination Survey III

Qingya Zhao¹, Xiaogang Lv¹, Qi Liu¹, Zhao Hu¹*and Yiqiang Zhan^{1,2}*

¹Department of Epidemiology, School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, China, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

The association between serum folate and all-cause mortality in general population remains unclear. The objective of this study was to investigate the potential association between serum folate concentrations and all-cause mortality in a large, prospective, long-term U.S. cohort. Our study included adults from the National Health and Nutrition Examination Survey (NHANES) III, and mortality data was obtained by linking with the National Death Index (NDI) until December 31, 2019. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) to assess the association between serum folate concentrations and all-cause mortality. A total of 12,862 participants were included in this cohort study. After a median follow-up of 26.4 years [interguartile range (IQR), 15.4-28.7 years], a total of 5,299 deaths were recorded. The risk of death was lower by 12% per 1.0 g/L increase in log-transformed serum folate concentrations (HR, 0.88; 95% CI, 0.83–0.94). Compared with the lowest quartiles of serum folate level, the risk of death was lower in the second (HR, 0.84; 95% CI, 0.72-0.97), third (HR, 0.78; 95% CI, 0.68-0.91) and the highest quartiles (HR, 0.78; 95% CI, 0.69-0.88) in multivariable-adjusted model. In subgroup analyses, the inverse association between serum folate and all-cause mortality remained statistically significant for women, men and non-Hispanic White people. Higher serum folate levels were found to be significantly associated with reduced risk of all-cause mortality. However, further studies are needed to verify these findings and explore the underlying mechanism.

KEYWORDS

folic acid, mortality, NHANES, cohort, folate

1 Introduction

Folate, also referred to as vitamin B9, serves as a coenzyme or cosubstrate in single-carbon transfers involved in nucleic acids synthesis and amino acid metabolism (1). One of the crucial reactions dependent on folate is the conversion of homocysteine to methionine in the synthesis of S-adenosyl-methionine (SAM). This conversion plays a vital role in preventing the

accumulation of homocysteine, which is a potential risk factor for various chronic diseases including cardiovascular diseases (CVD) (2, 3) and stroke (4, 5). Another reaction dependent on folate is the methylation of deoxyuridylate to thymidylate during Deoxyribonucleic acid (DNA) formation. This reaction is essential for accurate cell division and is believed to play a role in neural tube defects (6–8), megaloblastic anemia (9), and tumorigenesis (10, 11). Qualitative analysis revealed significant correlations between one-carbon metabolism nutrients and DNA methylation. Supplementation with folic acid alone or in combination with vitamin B12 significantly enhanced global DNA methylation in studies utilizing liquid chromatography-mass spectrometry, which exhibited markedly lower heterogeneity compared to other methods (12).

Research has evaluated the potential impact of folate on cancer risk with conflicting findings. Studies have demonstrated increased risk, no effect, and decreased risk (13-15). Many countries have implemented flour fortification programs by adding folic acid. Providing further insights into the full impact of folate on human health may provide more specific recommendations for policy makers. Moreover, many of these studies focused on specific populations or performed secondary analyses. For example, Li et al. identified a negative relationship between dietary folate intake and all-cause mortality in patients diagnosed with breast cancer (16). A study conducted on a Japanese cohort consisting of 3,050 adults found that higher serum folate concentrations were associated with lower risks of all-cause mortality. However, no significant associations were observed for CVD, respiratory, or cancer mortality (17). Conflicting with previous studies, a study indicated that dietary folate showed no significant association with either all-cause mortality or cancer-specific mortality among participants with cancer (18). A recent meta-analysis of randomized clinical trials (RCT) indicated that there were no significant relationships between folate supplementation and all-cause or CVD mortality. Furthermore, some RCTs even showed that folate supplementation was associated with elevated rates of all-cause mortality (19-22).

Thus, large-scale cohort studies are necessary to yield reliable results applicable to the general population. This study aims to establish the potential association between serum folate levels and all-cause mortality in the general U.S. population, using data obtained from a nationally representative sample of the National Health and Nutrition Examination Survey (NHANES).

2 Methods

2.1 Study design and population

Participants in this study were those who completed a study interview and examination as part of the NHANES III. The NHANES is a federally conducted survey in the United States that aims to provide representative data on the health and nutrition status of the noninstitutionalized population, which is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention. Information on demographic and socioeconomic characteristics, health-related behaviors and health conditions of participants were collected with household interviews. Physical measurements and laboratory tests were administered by trained laboratory technicians in mobile examination centers (MEC). The details of the sampling methods and procedures have been published elsewhere. A total of 33,994 participants were randomly selected and included in NHANES III. Participants who had missing information on serum folate or unreliable serum folate concentration (serum folate concentration <0.1 ng/mL or >100.0 ng/mL, or red blood cell (RBC) folate concentration >6.0 ng/mL or <1000.0 ng/mL) were excluded from the analysis (n = 10,293). Those who were younger than 18 years old or older than 90 years old (n = 7,053) were also excluded from the study. Participants having extreme body mass index (<18 or >30) and concurrently presenting extreme triceps skinfold thickness (<9.9 or >19.8 for females, <7.5 or >15 for males) (n = 3,786) were excluded, resulting in a final sample size of 12,862 participants.

NHANES is a public database and all participants provided a written informed consent, consistent with approval from the National Center for Health Statistics Research Ethics Review Board (NCHS ERB).

2.2 Serum folate measurement

Blood specimens of participants were collected in the MEC by trained laboratory technicians, and frozen specimens were shipped overnight according to the protocol. Serum folate concentrations were determined by the National Center for Environmental Health at the Centers for Disease Control and Prevention using a commercially available radioprotein binding assay kit (Quantaphase II, Bio-Rad Laboratories).

2.3 Outcome measurement

Mortality status was ascertained by linking the NDI public-access files up until December 31, 2019. All-cause mortality was defined as death due to any cause. Follow-up duration was calculated from the date of examination to the date of death or the end of 2019, whichever occurred first.

2.4 Potential confounders

Demographic information, including age at baseline, sex (men or women), education, ethnicity (non-Hispanic White people, non-Hispanic Black people, Hispanic American, or others), and military background (ever served in armed forces, never served in armed forces) were collected through a standard questionnaire by trained interviewers using a computer-assisted personal interviewing system. Educational attainment was classified as below high school (<9), high school (9–12), college or more (>15) in this study. Participants who had a physician-diagnosed history of diabetes or were taking diabetes pills or had a glycated hemoglobin value $\geq 6.5\%$ or a fasting plasma glucose ≥ 7.0 are classified as diabetic. Those with an average systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg were classified as hypertensive.

2.5 Statistical analysis

Descriptive characteristics at baseline are presented as mean with standard deviation (SD) for quantitative variables and as frequencies and percentages for categorical variables. Serum folate concentrations were categorized into quartiles after natural logarithmic transformation, and the first quartile was selected as the reference group. The survival rate function was estimated, and survival curves according to quartiles of serum folate showed significant differences by the log rank test. Adjusted for weights that account for the complex survey design (including oversampling, survey nonresponse, and post-stratification), cox proportional hazard regression models were employed to calculate the hazard ratios and corresponding 95% confidence intervals. Schoenfeld residuals were used to test the proportional hazards assumption, and no violation was observed. We constructed three cox models for the analysis. Beyond the unadjusted model, our multivariable models incorporated adjustments for age, sex, ethnicity, educational level, diabetes, and hypertension. Folate concentrations were examined as a continuous variable in Model 2 to assess the impact per one-unit change, and as quartiles in Model 3. Furthermore, we conducted stratified analyses by sex and ethnicity to assess potential effect modifications.

All analyses were conducted following the NHANES III analytical guidelines and were performed with R 4.2.3. Statistical significance was tested at p < 0.05, and all tests were 2-tailed.

3 Results

3.1 General characteristics

Of 12,862 participants included in this study, the mean (SD) age was 47.5 (20.4) years old and 6,232 (48.5%) were women. The general characteristics of the participants by sex are presented in Table 1. Compared with men participants, women participants were more likely to be younger, non-Hispanic White people, more educated, never served in armed forces and tended to have lower prevalence rates of hypertension.

3.2 Associations between serum folate with all-cause mortality

During a median follow-up of 26.4 (IQR, 15.4–28.7) years, a total of 5,299 deaths were recorded. Hazard ratios for all-cause mortality according to serum folate were presented in Table 2. An inverse association between serum folate and all-cause mortality was observed. Participants with per $1.0 \mu g/L$ increase in log-transformed serum folate concentrations were associated with a 12% decreased risk of all-cause mortality after adjusting for age, sex, ethnicity, educational level, diabetes and hypertension (HR, 0.88; 95% CI, 0.83–0.94). The crude HRs of all-cause mortality were 0.83 (95% CI, 0.70–0.99), 0.75 (95% CI, 0.63–0.88), and 0.72 (95% CI, 0.63–0.83) for the second, third and highest quartiles of folate, respectively. After multivariable adjustment, compared with individuals in the first quartile of serum folate, those in the second, the third, and the highest quartile had 0.84 (95% CI, 0.72–0.97), 0.78 (95% CI, 0.68–0.91), and 0.78 (95% CI, 0.69–0.88) -times lower risk of all-cause mortality. The survival curves are presented in Figure 1.

3.3 Stratified analyses

The results of the subgroup analyses are presented in Table 3. The association between serum concentrations of folate and all-cause mortality was attenuated when stratified by sex. The crude HRs and

TABLE 1 Baseline characteristics of the study population.

Variable	Men (<i>n</i> = 6,630)	Women (<i>n</i> = 6,232)				
Age (year)	47.9 ± 20.2	47.1 ± 20.6				
Race/Ethnicity, n (%)						
Non-Hispanic White people	2,730 (41.2%)	2,830 (45.4%)				
Non-Hispanic Black people	1,704 (25.7%)	1,542 (24.7%)				
Mexican-American	1,944 (29.3%)	1,583 (25.4%)				
Other Hispanic	252 (3.8%)	277(4.4%)				
Education, <i>n</i> (%)						
<high school<="" td=""><td>1,836 (27.7%)</td><td>1,440 (23.1%)</td></high>	1,836 (27.7%)	1,440 (23.1%)				
High school	2,807 (42.7%)	2,832 (45.4%)				
Some college or more	1,919 (28.9%)	1,914 (30.7%)				
Uncertain*	68 (1.0%)	46 (0.7%)				
Military, n (%)						
Ever served in armed forces	1,948 (29.4%)	1,163 (18.7%)				
Never served in armed forces	4,632 (69.9%)	5,036 (80.8%)				
Uncertain*	50 (0.8%)	33 (0.5%)				
Diabetes, n (%)	734 (11.1%)	629 (10.1%)				
Hypertension, <i>n</i> (%)	1,572 (23.7%)	1,305 (20.9%)				

*Categorized based on self-report in the NHANES interview.

TABLE 2 Hazard ratio (HRs) and 95% CIs for all-cause mortality according to serum concentrations of folate.

Folate/ (µg L ^{−1})*	HR (95% CI)	HR (95% Cl)a	HR (95% Cl)a
Q1 (-0.92, 1.28]	1.00	-	1.00
Q2 (1.28, 1.70]	0.83 (0.70-0.99)	-	0.84 (0.72-0.97)
Q3 (1.70, 2.15]	0.75 (0.63–0.88)	-	0.78 (0.68-0.91)
Q4 (2.15, 4.55]	0.72 (0.63-0.83)	-	0.78 (0.69–0.88)
Continuous	-	0.88 (0.83-0.94)	-

*Natural logarithmic transformed.*Adjusted for age, sex (male or female), ethnicity (non-Hispanic White people, non-Hispanic Black people, Mexican-American, or other), educational level (below high school, high school, college or more), diabetes (yes or no) and hypertension (yes or no).



adjusted HRs remained significant for the third and the highest quartiles, whereas that for the second quartile failed to reach statistical significance in both sexes.

	Folate/(μ g L ⁻¹)*	HR (95% CI)	HR (95% CI)a	HR (95% CI)b		
		Gender				
Male (<i>n</i> = 6,630)	Q1 (-0.92, 1.28]	1.00	_	1.00		
	Q2 (1.28, 1.70]	0.86 (0.72, 1.03)	_	0.85 (0.72, 1.00)		
	Q3 (1.70, 2.15]	0.76 (0.62, 0.94)	_	0.79 (0.65, 0.95)		
	Q4 (2.15, 4.55]	0.79 (0.67, 0.94)	_	0.82 (0.70, 0.94)		
	Continuous	_	0.89 (0.83, 0.96)	_		
Female (<i>n</i> = 6,232)	Q1 (-0.92, 1.28]	1.00	_	1.00		
	Q2 (1.28, 1.70]	0.80 (0.63, 1.01)	_	0.80 (0.64, 1.01)		
	Q3 (1.70, 2.15]	0.76 (0.64, 0.90)	_	0.78 (0.65, 0.93)		
	Q4 (2.15, 4.55]	0.72 (0.61, 0.84)	_	0.74 (0.63, 0.87)		
	Continuous	_	0.88 (0.81, 0.96)	_		
Ethnicity						
Non-Hispanic White people	Q1 (-0.92, 1.28]	1.00	_	1.00		
(<i>n</i> = 5,560)	Q2 (1.28, 1.70]	0.80 (0.70, 0.91)	_	0.80 (0.71, 0.91)		
	Q3 (1.70, 2.15]	0.73 (0.62, 0.85)	_	0.76 (0.66, 0.88)		
	Q4 (2.15, 4.55]	0.70 (0.60, 0.80)	-	0.75 (0.66, 0.85)		
	Continuous	_	0.87 (0.82, 0.93)	_		
Non-Hispanic Black people (<i>n</i> = 3,246)	Q1 (-0.92, 1.28]	1.00	_	1.00		
	Q2 (1.28, 1.70]	0.99 (0.84, 1.17)	_	0.97 (0.83, 1.15)		
	Q3 (1.70, 2.15]	0.93 (0.79, 1.09)	_	0.90 (0.76, 1.06)		
	Q4 (2.15, 4.55]	0.92 (0.75, 1.12)	_	0.88 (0.73, 1.07)		
	Continuous	_	0.92 (0.81, 1.04)	-		
Mexican-American (<i>n</i> = 3,527)	Q1 (-0.92, 1.28]	1.00	_	1.00		
	Q2 (1.28, 1.70]	0.81 (0.61, 1.07)	_	0.75 (0.56, 1.01)		
	Q3 (1.70, 2.15]	0.88 (0.73, 1.06)	_	0.87 (0.69, 1.09)		
	Q4 (2.15, 4.55]	0.66 (0.56, 0.77)	-	0.70 (0.58, 0.84)		
	Continuous	-	0.84 (0.74, 0.95)	-		
Other (<i>n</i> = 529)	Q1 (-0.92, 1.28]	1.00	-	1.00		
	Q2 (1.28, 1.70]	0.99 (0.54, 1.80)	_	1.04 (0.60, 1.81)		
	Q3 (1.70, 2.15]	0.72 (0.27, 1.95)	_	0.73 (0.30, 1.77)		
	Q4 (2.15, 4.55]	0.90 (0.47, 1.73)	_	0.78 (0.42, 1.45)		
	Continuous	_	0.90 (0.64, 1.26)	_		

TABLE 3 Hazard ratio (HRs) and 95% CIs for all-cause mortality according to serum concentrations of folate, stratified by gender and ethnicity.

*Natural logarithmic transformed.*Adjusted for age, sex (male or female), ethnicity (non-Hispanic White people, non-Hispanic Black people, Mexican-American, or other), educational level (below high school, high school, college or more), diabetes (yes or no) and hypertension (yes or no). The strata variable was not included when stratifying by itself.

^bAdjusted for age, sex (male or female), ethnicity (non-Hispanic White people, non-Hispanic Black people, Mexican-American, or other), educational level (below high school, high school, college or more), diabetes (yes or no) and hypertension (yes or no). The strata variable was not included when stratifying by itself.

However, we can observe a statistically significant association between serum folate and all-cause mortality only for non-Hispanic White people. The crude HRs and adjusted HRs for increasing quartiles and continuous concentrations of serum folate remained statistically significant for non-Hispanic White people. In addition, for Mexican-Americans, the HRs for continuous concentrations of folate and for the fourth quartile were also significant. As for non-Hispanic Black people and other ethnicities, no statistical significance was observed in the three models.

4 Discussion

In this large, prospective cohort study of adults in the U.S., we observed a significant association between serum folate and all-cause mortality. Briefly, higher serum folate was significantly associated with lower all-cause mortality risk in general population. This inverse association remained statistically significant for women, men and non-Hispanic White people. However, in subgroup analyses this association became weaker among Mexican-Americans and nonsignificant for non-Hispanic Black people, and individuals of other ethnicities. As is reported, ethnicity is one of the significant determinants of RBC and serum folate concentrations. Compared with the White people, RBC and serum folate concentrations were significantly lower in the Black people (23). Another study, based on the NHANES 1999–2016, found similar results. The non-Hispanic White people showed higher folate concentrations compared to the non-Hispanic Black people and the Hispanic (24). In addition to folic acid intake from fortification and supplements, blood folate concentrations depend on folate intake from natural foods and genetic variation in the population. Variations in dietary habits, demographic characteristics, and specific genes like the MTHFR variant are significant contributors to the effects of folate across different ethnicities. In addition, the "other" ethnicities may not have had sufficient power due to smaller sample sizes in this study.

4.1 Comparison with previous studies

Our findings are consistent with several previous studies that have demonstrated an inverse association between folate levels and all-cause mortality. In a prospective cohort conducted in Israel, it was observed that older adults with serum folate deficiency (<4.4 ng/mL) had an increased risk of dementia and nearly triple the risk of all-cause mortality (25). Another study conducted in Western Australia also found negative associations between serum folate and RBC folate levels with certain types of cancer risk, indicating that protective effects of folate on causespecific mortality (26). Bo et al. found that intake of dietary folate, which was assessed by 24 h diet recall, was in relation to all-cause mortality and CVD mortality (27). This study measured folate exposure by another method, but came to the same conclusion, providing more convincing evidence for the inverse association between folate and mortality.

However, some other studies reported inconsistent results. A 10 year cohort study found that there was no significant association between either serum folate (Adjusted HR, 1.03; 95% CI, 0.91-1.16) or RBC folate (Adjusted HR, 1.16; 95% CI, 0.99-1.36) with mortality risk among hypertensive patients with elevated homocysteine (28). Different from our study, it was focus on hypertensive patients with elevated homocysteine, resulting in a small sample of only 1,753 participants. This small sample size may not have enough power to find such an association. Indeed, two randomized, double-blind, placebocontrolled clinical trials, including 6,837 participants, reported that treatment with folate plus vitamin B12 was even associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway (19). In general, the conflicting results observed in these studies can be attributed to several factors, including variations in the measurement of exposure, differences in study populations and regions. Furthermore, inconsistencies can also be influenced by sample size and duration of follow-up.

4.2 Potential mechanisms

Although the mechanisms underlying how a low level of folate status contributes to mortality remain unclear, several possible

explanations can be considered. A hypothesis pertains to alterations in DNA methylation. Folate plays a crucial role in the synthesis of SAM, the principal methyl donor in most cellular reactions, including the methylation of cytosine in the DNA molecule (29). Regional hypomethylation is associated with alterations in chromatin conformation and with alterations in interaction between DNA and methyl-specific proteins, promoting genomic instability (30). Folate deficiency disturbs cytosine methylation, leading to global DNA hypomethylation and/or changes in gene-specific methylation and inappropriate protooncogene activation (30, 31). Within the methionine cycle, 5-methyltetrahydrofolate methylates homocysteine to methionine, preventing the continued buildup of homocysteine (32). Folate deficiency leads to an increase in blood homocysteine concentrations, and an elevated level of homocysteine concentrations has shown a significant association with the incidence of various diseases, such as heart disease (33, 34), tumorigenesis (35, 36), stroke (37, 38), and diabetes mellitus (39). Another hypothesis pertains to how folate deficiency disrupts the synthesis and repair of DNA. Folate is critical for the synthesis of both purines and the pyrimidine nucleoside thymidine. Deoxyuridine monophosphate is converted to thymidine monophosphate with 5,10-methylenetetrahydrofolate as the methyl donor (40). In addition, 5,10-formyltetrahydrofolate is involved in the production of both adenosine and guanosine (41, 42). The production of these DNA precursors is essential for normal DNA synthesis and repair. When folate levels are limited, it leads to an imbalance in purine and pyrimidine DNA precursors, ultimately inhibiting normal DNA repair processes. Additionally, uracil, an atypical component in DNA, is mistakenly inserted into the DNA molecule instead of thymidine, leading to DNA strand breakage, chromosomal damage, and malignant transformation (43). Thus, low levels of folate status may be associated with tumorigenesis (41), aging (2), and related diseases (7, 8). Due to the above mechanisms, low level of folate may be associated with various related diseases and mortality, and mechanistic studies are warranted to clarify the roles of serum folate in the long-term health of individuals.

4.3 Strengths and limitations

The strengths of our study are its prospective design, long-term follow-up duration, and large national representative samples, adjusted for weights to account for the complex survey design, survey nonresponse, and post-stratification. In addition, the measurements of serum folate concentrations and covariates are generally reliable because they were under the well-designed guidance of NCHS of the United States, a professional national organization.

There are some limitations to our study as well. First, the measurement of circulating folate was merely based on a single serum examination at baseline, which may not reflect the longterm folate status accurately. Second, the mortality outcomes of participants were determined by linkage to the NDI through a probabilistic match, which might result in misclassification. Third, residual or unmeasured confounding cannot be entirely excluded. In addition, we failed to consider whether participants have used folic acid supplements due to insufficient data. Although few prospective studies have examined the association between serum folate levels and all-cause mortality in general population, the observational design of our study does not allow us to make causal inference from the results.

It is important to address the limitation related to the measurement of dietary adherence using the Perceived Dietary Adherence Questionnaire. This limitation stems from the unavailability of data on the questionnaire in the NHANES III public database, which restricted the direct assessment of dietary adherence through this specific tool. Therefore, future studies aiming to explore the relationship between dietary adherence and health outcomes should consider incorporating more detailed dietary assessment methods to provide a comprehensive understanding of dietary patterns and their impact on various health parameters.

The inverse association observed between folate intake and mortality suggests that maintaining a healthy diet is crucial for overall health. Consuming foods rich in folate, such as vegetables, animal liver, and egg yolks, may offer protection against related diseases. Nevertheless, it is worth noting that our study focused solely on the nutrient folate. Some studies have highlighted the role of dietary patterns rather than single nutrient as crucial factors in chronic diseases (44, 45). Lifestyle risk factors such as unhealthy diet, lack of physical activity, smoking, and excessive alcohol consumption are correlated and tend to co-occur with other behaviors within the population (46). Additionally, due to the intricate and interactions between nutrients, focusing on a single nutrient may underestimate its impact on health. Recently, researchers have attempted to cluster lifestyle risk factors together. The combination of two or more unhealthy lifestyle behaviors is generally linked to a higher risk of disease than would be expected from each individual risk factor alone (47, 48). Therefore, our study may underestimate the effect of folate, and more detailed comprehensive assessments of multiple nutrients, dietary habits, and other lifestyle habits are needed.

5 Conclusion

In this large, prospective cohort study, we found a significant inverse association between serum folate and overall mortality risk. Specifically, higher serum folate was associated with a reduced risk of all-cause mortality. Nevertheless, further studies are necessary to fully comprehend the underlying mechanisms of folate on mortality risk.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: NHAMES (https://www.cdc.gov/nchs/nhanes/index.htm).

References

Bailey LB, Caudill MA. Folate. Present Knowledge in Nutrition, (2012). 321–342
Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects

of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. *Arch Intern Med.* (2010) 170:1622–31. doi: 10.1001/archinternmed.2010.348

Ethics statement

The studies involving humans were approved by School of Public Health, Sun-Yat-Sen University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

QZ: Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing. XL: Validation, Writing – review & editing, Methodology. QL: Validation, Writing – review & editing, Methodology. ZH: Validation, Conceptualization, Supervision, Writing – review & editing, Writing – original draft. YZ: Validation, Conceptualization, Supervision, Writing – review & editing, Writing – original draft.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

Data and codebooks used in this study are all available on this public website (https://www.cdc.gov/nchs/nhanes/index.htm). The authors thank the participants of the NHANES for their contributions to this work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

3. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA. (2004) 291:565–75. doi: 10.1001/jama.291.5.565

^{4.} Tian T, Yang KQ, Cui JG, Zhou LL, Zhou XL. Folic acid supplementation for stroke prevention in patients with cardiovascular disease. *Am J Med Sci.* (2017) 354:379–87. doi: 10.1016/j.amjms.2017.05.020

5. Huo Y, Qin X, Wang J, Sun N, Zeng Q, Xu X, et al. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. *Int J Clin Pract.* (2012) 66:544–51. doi: 10.1111/j.1742-1241.2012.02929.x

6. Erickson JD. Folic acid and prevention of spinal bifida and anencephaly. 10 years after the U.S. Public Health Service recommendation. *MMWR Recomm Rep.* (2002) 51:1–3.

7. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B deficiencies during pregnancy on fetal, infant, an child development. *Food Nutr Bull.* (2008) 29:S101–11. doi: 10.1177/15648265080292S114

8. Scott JM. Evidence of folic acid and folate in the prevention of neural tube defects. *Bibl Nutr Dieta*. (2001) 55:59465. doi: 10.1159/000059465

9. Green R, Datta A. Megaloblastic anemias nutritional and other causes. *Med Clin North Am.* (2017) 101:297–317. doi: 10.1016/j.mcna.2016.09.013

10. He HD, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological studies. *Int J Food Sci Nutr.* (2014) 65:286–92. doi: 10.3109/09637486.2013.866641

11. Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem. (1999) 10:66–88. doi: 10.1016/S0955-2863(98)00074-6

12. Amenyah SD, Hughes CF, Ward M, Rosborough S, Deane J, Thursby SJ, et al. Influence of nutrients involved in one-carbon metabolism on DNA methylation in adults-a systematic review and meta-analysis. *Nutr Rev.* (2020) 78:647–66. doi: 10.1093/ nutrit/nuz094

13. Pieroth R, Paver S, Day S, Lammersfeld C. Folate and its impact on cancer risk. *Curr Nutr Rep.* (2018) 7:70–84. doi: 10.1007/s13668-018-0237-y

14. Wang R, Zheng Y, Huang JY, Zhang AQ, Zhou YH, Wang JN. Folate intake, serum folate levels, and prostate cancer risk: a meta-analysis of prospective studies. *BMC Public Health*. (2014) 14:1326. doi: 10.1186/1471-2458-14-1326

15. Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M. Cancer risk with folic acid supplements: a systematic review and meta-analysis. *BMJ Open*. (2012) 2:e000653. doi: 10.1136/bmjopen-2011-000653

16. Li B, Lu Y, Wang L, Zhang CX. Folate intake and breast cancer prognosis: a metaanalysis of prospective observational studies. *Eur J Cancer Prev.* (2015) 24:113–21. doi: 10.1097/CEJ.000000000000028

17. Chen SM, Honda T, Hata J, Sakata S, Furuta Y, Yoshida D, et al. High serum folate concentrations are associated with decreased risk of mortality among Japanese adults. *J Nutr.* (2021) 151:657–65. doi: 10.1093/jn/nxaa382

 Xu XR, Gammon MD, Wetmur JG, Bradshaw PT, Teitelbaum SL, Neugut AI, et al. B-vitamin intake, one-carbon metabolism, and survival in a population-based study of women with breast cancer. *Cancer Epidemiol Biomarkers Prev.* (2008) 17:2109–16. doi: 10.1158/1055-9965.EPI-07-2900

19. Ebbing M, Bonaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B. *JAMA J Am Med Assoc*. (2009) 302:2119–26. doi: 10.1001/jama.2009.1622

20. Khan SU, Khan MU, Riaz H, Valavoor S, Zhao D, Vaughan L, et al. Effects of nutritional supplements and dietary interventions on cardiovascular outcomes an umbrella review and evidence map. *Ann Intern Med.* (2019) 171:190. doi: 10.7326/M19-0341

21. Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR. Dietary supplements and mortality rate in older women. *Arch Intern Med.* (2011) 171:1625–33. doi: 10.1001/archinternmed.2011.445

22. Roswall N, Olsen A, Christensen J, Hansen L, Dragsted LO, Overvad K, et al. Micronutrient intake in relation to all-cause mortality in a prospective Danish cohort. *Food Nutr Res.* (2012) 56:5466. doi: 10.3402/fnr.v56i0.5466

23. Jones KS, Collins D, Meadows SR, Koulman A, Page P. National Diet and nutrition survey data reveal a decline in folate status in the United Kingdom population between 2008 and 2019. *Am J Clin Nutr.* (2023) 118:1182–91. doi: 10.1016/j.ajcnut.2023.10.006

24. Pfeiffer CM, Sternberg MR, Zhang M, Fazili Z, Storandt RJ, Crider KS, et al. Folate status in the US population 20 y after the introduction of folic acid fortification. *Am J Clin Nutr.* (2019) 110:1088–97. doi: 10.1093/ajcn/nqz184

25. Rotstein A, Kodesh A, Goldberg Y, Reichenberg A, Levine SZ. Serum folate deficiency and the risks of dementia and all-cause mortality: a national study of old age. *Evid Based Ment Health.* (2022) 25:63–8. doi: 10.1136/ebmental-2021-300309

26. Rossi E, Hung J, Beilby JP, Knuiman MW, Divitini ML, Bartholomew H. Folate levels and cancer morbidity and mortality: prospective cohort study from Busselton, Western Australia. *Ann Epidemiol.* (2006) 16:206–12. doi: 10.1016/j.annepidem.2005.03.010

27. Bo YC, Xu HD, Zhang HH, Zhang JX, Wan ZX, Zhao X, et al. Intakes of folate, vitamin B6, and vitamin B12 in relation to all-cause and cause-specific mortality: a National population-based cohort. *Nutrients*. (2022) 14:112253. doi: 10.3390/nu14112253

28. Zhou L, Huang H, Wen XX, Chen Y, Liao J, Chen FL, et al. Associations of serum and red blood cell folate with all-cause and cardiovascular mortality among hypertensive patients with elevated homocysteine. *Front Nutr.* (2022) 9:849561. doi: 10.3389/fnut.2022.849561

29. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. *Am J Clin Nutr.* (1992) 55:131–8. doi: 10.1093/ajcn/55.1.131

30. Caiafa P, Zampieri M. DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem. (2005) 94:257–65. doi: 10.1002/jcb.20325

31. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for Folate's role. *Adv Nutr*. (2012) 3:21–38. doi: 10.3945/an.111.000992

32. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. *Circulation*. (1996) 94:2410–6.

33. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. *Nutr J.* (2015) 14:6. doi: 10.1186/1475-2891-14-6

34. Kalra DK. Homocysteine and cardiovascular disease. *Curr Atheroscler Rep.* (2004) 6:101–6. doi: 10.1007/s11883-004-0097-3

35. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. *Cancer Res.* (1996) 56:4862–4.

36. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res.* (1997) 57:1098–102.

37. Chen YP, Zou H, Peng MD, Chen Y. Association between homocysteine levels in acute stroke and poststroke depression: a systematic review and meta-analysis. *Brain Behavior*. (2022) 12:e2626. doi: 10.1002/brb3.2626

38. Hankey GJ, Eikelboom JW. Homocysteine and stroke. *Curr Opin Neurol.* (2001) 14:95–102. doi: 10.1097/00019052-200102000-00015

39. Mursleen MT, Riaz S. Implication of homocysteine in diabetes and impact of folate and vitamin B12 in diabetic population. *Diabetes Metab Syndr Clin Res Rev.* (2017) 11:S141–6. doi: 10.1016/j.dsx.2016.12.023

40. Mc Auley MT, Mooney KM, Salcedo-Sora JE. Computational modelling folate metabolism and DNA methylation: implications for understanding health and ageing. *Brief Bioinform*. (2016) 19:bbw116–7. doi: 10.1093/bib/bbw116

41. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis. (2011) 34:101–9. doi: 10.1007/ s10545-010-9128-0

42. Reidy JA. Role of deoxyridine incorporation and DNA repair in the expression of human chromosomal fragile sites. *Mutat Res/Fundamental Mol Mech Mutag.* (1988) 200:215–20. doi: 10.1016/0027-5107(88)90085-1

43. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. *Proc Natl Acad Sci.* (1997) 94:3290–5. doi: 10.1073/pnas.94.7.3290

44. Nikniaz L, Mahmudiono T, Jasim SA, Vajdi M, Thangavelu L, Farhangi MA. Nutrient pattern analysis of mineral based, simple sugar based, and fat based diets and risk of metabolic syndrome: a comparative nutrient panel. *BMC Endocr Disord*. (2022) 22:51. doi: 10.1186/s12902-022-00963-2

45. Vajdi M, Nikniaz L, Pour Asl AM, Abbasalizad FM. Lifestyle patterns and their nutritional, socio-demographic and psychological determinants in a community-based study: a mixed approach of latent class and factor analyses. *PLoS One.* (2020) 15:e0236242. doi: 10.1371/journal.pone.0236242

46. Vajdi M, Karimi A, Farhangi MA, Ardekani AM. The association between healthy lifestyle score and risk of metabolic syndrome in Iranian adults: a cross-sectional study. *BMC Endocr Disord.* (2023) 23:16. doi: 10.1186/s12902-023-01270-0

47. Slattery ML, Potter JD. Physical activity and colon cancer: confounding or interaction? *Med Sci Sports Exerc.* (2002) 34:913–9. doi: 10.1097/00005768-200206000-00002

48. Breslow L, Enstrom JE. Persistence of health habits and their relationship to mortality. *Prev Med.* (1980) 9:469–83. doi: 10.1016/0091-7435(80)90042-0